Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer

The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of penile cancer (PeCa). We aimed to assess whether members this serve as biomarkers and targets systemic therapy. Tissue primary from treatment-naïve PeCa patients was used tissue microarray analysis. Immunohistochemical staining performed with antibodies against AKT, pAKT, mTOR, pmTOR, pS6, pPRAS, p4EBP1, S6K1 pp70S6K. Protein expression correlated clinicopathological characteristics well overall survival (OS), disease-specific (DSS), recurrence-free (RFS) metastasis-free (MFS). AKT inhibition tested in two primarily established, cell lines by capivasertib analysis viability chemotaxis. A total 76 surgically treated invasive were included. Higher significantly more prevalent high-grade tumors predictive DSS OS the Kaplan–Meier analysis, independent predictor worse multivariate regression Treatment pan-AKT inhibitor induced a significant downregulation both pAKT decreased Selected protein candidates mTOR/AKT signaling demonstrate association histological parameters patients, whereas appears be most promising one.